DK3390395T3 - Forbindelser, der kan anvendes som kinase-inhibitorer - Google Patents

Forbindelser, der kan anvendes som kinase-inhibitorer Download PDF

Info

Publication number: DK3390395T3
Authority: DK; Denmark
Prior art keywords: compounds; kinase inhibitors; kinase; inhibitors
Prior art date: 2015-12-16

Application number

DK16816363.2T

Other languages

English (en)

Inventor

Nicolas Guisot

Original Assignee

Loxo Oncology Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-12-16

Filing date

2016-12-16

Publication date

2020-09-28

2015-12-16 Priority claimed from GBGB1522245.8A external-priority patent/GB201522245D0/en

2016-08-15 Priority claimed from GBGB1613945.3A external-priority patent/GB201613945D0/en

2016-12-16 Application filed by Loxo Oncology Inc filed Critical Loxo Oncology Inc

2020-09-28 Application granted granted Critical

2020-09-28 Publication of DK3390395T3 publication Critical patent/DK3390395T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

DK16816363.2T 2015-12-16 2016-12-16 Forbindelser, der kan anvendes som kinase-inhibitorer DK3390395T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB1522245.8A GB201522245D0 (en)	2015-12-16	2015-12-16	Compounds useful as kinase inhibitors
GBGB1613945.3A GB201613945D0 (en)	2016-08-15	2016-08-15	Compounds useful as kinase inhibitors
PCT/GB2016/053968 WO2017103611A1 (en)	2015-12-16	2016-12-16	Compounds useful as kinase inhibitors

Publications (1)

Publication Number	Publication Date
DK3390395T3 true DK3390395T3 (da)	2020-09-28

Family

ID=57590725

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK16816363.2T DK3390395T3 (da)	2015-12-16	2016-12-16	Forbindelser, der kan anvendes som kinase-inhibitorer

Country Status (37)

Country	Link
US (8)	US10695323B2 (da)
EP (2)	EP3782994B1 (da)
JP (3)	JP6731483B2 (da)
KR (2)	KR102215792B1 (da)
CN (9)	CN114605327B (da)
AU (4)	AU2016373530B2 (da)
CA (1)	CA3008488C (da)
CL (1)	CL2018001591A1 (da)
CO (1)	CO2018006164A2 (da)
CR (1)	CR20180367A (da)
CY (2)	CY1123561T1 (da)
DK (1)	DK3390395T3 (da)
EA (1)	EA035132B1 (da)
ES (2)	ES2828431T3 (da)
FI (1)	FIC20240004I1 (da)
FR (1)	FR24C1009I2 (da)
HR (1)	HRP20201835T1 (da)
HU (2)	HUE051921T2 (da)
IL (4)	IL285976B2 (da)
LT (2)	LT3390395T (da)
MA (2)	MA55064A (da)
MD (1)	MD3390395T2 (da)
MX (2)	MX380907B (da)
MY (2)	MY200590A (da)
NL (1)	NL301262I2 (da)
NO (1)	NO2024008I1 (da)
NZ (1)	NZ743553A (da)
PE (3)	PE20220502A1 (da)
PH (1)	PH12018501268A1 (da)
PT (1)	PT3390395T (da)
RS (1)	RS60982B9 (da)
SG (2)	SG10202012498TA (da)
SI (1)	SI3390395T1 (da)
TN (1)	TN2018000213A1 (da)
UA (2)	UA127863C2 (da)
WO (1)	WO2017103611A1 (da)
ZA (4)	ZA201804137B (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201410430D0 (en)	2014-06-11	2014-07-23	Redx Pharma Ltd	Compounds
HK1258779A1 (zh)	2015-09-16	2019-11-22	Loxo Oncology Inc.	用於治療癌症的作為btk抑制劑的吡唑並嘧啶衍生物
SI3390395T1 (sl)	2015-12-16	2020-11-30	Loxo Oncology, Inc.	Spojine uporabne kot inhibitorji kinaz
GB201801226D0 (en)	2018-01-25	2018-03-14	Redx Pharma Plc	Modulators of Rho-associated protein kinase
KR20210028144A (ko) *	2018-04-06	2021-03-11	블랙 벨트 티엑스 리미티드	Atf6 저해제 및 그의 용도
CN112119063B (zh) *	2018-05-18	2023-10-17	富士胶片株式会社	3-二氟甲基吡唑化合物的制造方法及3-二氟甲基吡唑-4-羧酸化合物的制造方法以及吡唑烷化合物
EP3829543A1 (en) *	2018-07-31	2021-06-09	Loxo Oncology, Inc.	Spray-dried dispersions and formulations of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoro propan-2-yl)-1h-pyrazole-4-carboxamide
CN114206852A (zh)	2019-08-09	2022-03-18	卡尔维斯塔制药有限公司	血浆激肽释放酶抑制剂
US20220273593A1 (en) *	2019-09-19	2022-09-01	Johann Wolfgang Goethe-Universität Frankfurt am Main	Compounds and compositions for treating kidney disease
CN110724135B (zh) *	2019-11-18	2023-04-28	上海医药工业研究院有限公司	一种艾拉普林中间体及其制备方法
WO2021113497A1 (en) *	2019-12-06	2021-06-10	Loxo Oncology, Inc.	Dosing of a bruton's tyrosine kinase inhibitor
CN120118089A (zh)	2020-01-02	2025-06-10	迪哲(江苏)医药股份有限公司	Btk抑制剂
JP2023518006A (ja) *	2020-03-12	2023-04-27	フォチョン・バイオサイエンシーズ・リミテッド	キナーゼ阻害剤としての化合物
TWI809489B (zh) *	2020-09-10	2023-07-21	美商絡速藥業公司	用於製備(s)-5-胺基-3-(4-((5-氟-2-甲氧基苯甲醯胺基)甲基)苯基)-1-(1,1,1-三氟丙烷-2-基)-1h-吡唑-4-甲醯胺之方法及中間體
CN112386597B (zh) *	2020-10-15	2022-03-15	天津济坤医药科技有限公司	泽布替尼在制备治疗肺纤维化疾病药物中的应用
WO2022140246A1 (en)	2020-12-21	2022-06-30	Hangzhou Jijing Pharmaceutical Technology Limited	Methods and compounds for targeted autophagy
CN116348453B (zh) *	2021-04-25	2025-07-04	烨辉医药科技(上海)有限公司	杂芳族甲酰胺化合物及其用途
BR112023021235A2 (pt)	2021-05-14	2023-12-12	Loxo Oncology Inc	Formas cocristalinas de um inibidor da tirosina quinase de bruton
KR20240029070A (ko) *	2021-07-01	2024-03-05	항저우 힐젠 테라퓨틱스 컴퍼니 리미티드	브루톤 티로신 키나아제, 이의 돌연변이체 분해제, 조성물 및 응용
WO2023284765A1 (zh) *	2021-07-16	2023-01-19	深圳市塔吉瑞生物医药有限公司	取代的吡唑类化合物及包含该化合物的组合物及其用途
MX2024007328A (es)	2021-12-14	2024-09-30	Crossfire Oncology Holding B V	Inhibidores macrociclicos de btk.
WO2023143355A1 (en) *	2022-01-28	2023-08-03	Hansoh Bio Llc	Azacycle amide derivative, preparation methods and medicinal uses thereof
EP4474377A4 (en) *	2022-03-03	2025-07-30	Shenzhen Targetrx Inc	Cycloalkyl or heterocyclyl substituted heteroaryl compound, and composition and use thereof
EP4493557A1 (en) *	2022-03-18	2025-01-22	Insilico Medicine IP Limited	Pyrazole membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof
CN115894376B (zh) *	2022-12-15	2025-05-16	南京雷正医药科技有限公司	一种芳香族酰胺类化合物、药物组合物及其用途
IL322630A (en)	2023-02-22	2025-10-01	Assia Chem Ind Ltd	Solid forms of pirobrutinib
WO2024245578A1 (en)	2023-06-02	2024-12-05	Netherlands Translational Research Center Holding B.V.	Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor
WO2024246287A1 (en)	2023-06-02	2024-12-05	Crossfire Oncology Holding B.V.	Medical use of a macrocyclic reversible btk inhibitor
WO2024245577A1 (en)	2023-06-02	2024-12-05	Netherlands Translational Research Center Holding B.V.	Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor
WO2024256568A1 (en)	2023-06-13	2024-12-19	Crossfire Oncology Holding B.V.	Salt and crystal forms of a macrocyclic btk inhibitor
WO2024256574A1 (en)	2023-06-13	2024-12-19	Crossfire Oncology Holding B.V.	Process for preparing macrocyclic btk inhibitors
KR20250046558A (ko)	2023-09-27	2025-04-03	임창섭	5g 사물인터넷 기반 하드월렛 간의 디지털자산 안심이체 시스템
WO2025124496A1 (zh) *	2023-12-13	2025-06-19	正大天晴药业集团股份有限公司	含有吡唑环和双环杂芳基的化合物、其药物组合物及用途
WO2025137329A1 (en) *	2023-12-22	2025-06-26	Neupharma, Inc	Certain chemical entities, compositions, and methods
CN119059974B (zh) *	2024-08-12	2025-10-28	武汉九州钰民医药科技有限公司	一种吡托布鲁替尼的制备方法
CN119059973A (zh) *	2024-08-12	2024-12-03	武汉九州钰民医药科技有限公司	一种吡托布鲁替尼的合成工艺
CN120504661B (zh) *	2025-07-14	2025-11-07	复旦大学	Alkbh8小分子抑制剂及其制备方法和用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SK3812002A3 (en)	1999-09-17	2003-09-11	Abbott Gmbh & Co Kg	Pyrazolopyrimidines as therapeutic agents
US6921763B2 (en)	1999-09-17	2005-07-26	Abbott Laboratories	Pyrazolopyrimidines as therapeutic agents
US6291504B1 (en) *	1999-10-20	2001-09-18	Dupont Pharmaceuticals Company	Acylsemicarbazides and their uses
US20030225098A1 (en)	2002-03-21	2003-12-04	Hirst Gavin C.	Kinase inhibitors
PL2529622T3 (pl)	2006-09-22	2018-07-31	Pharmacyclics Llc	Inhibitory kinazy tyrozynowej brutona
CN101553224A (zh) *	2006-10-06	2009-10-07	艾博特公司	新型咪唑并噻唑和咪唑并唑
US8987233B2 (en)	2006-11-03	2015-03-24	Pharmacyclics, Inc.	Bruton's tyrosine kinase activity probe and method of using
CA2681756C (en)	2007-03-28	2015-02-24	Pharmacyclics, Inc.	Inhibitors of bruton's tyrosine kinase
RU2536584C2 (ru)	2008-06-27	2014-12-27	Авила Терапьютикс, Инк.	Гетероарильные соединения и их применение
US8338439B2 (en)	2008-06-27	2012-12-25	Celgene Avilomics Research, Inc.	2,4-disubstituted pyrimidines useful as kinase inhibitors
CN102159214A (zh)	2008-07-16	2011-08-17	药品循环公司	用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
PT2324008E (pt) *	2008-07-24	2012-06-25	Nerviano Medical Sciences Srl	3,4-diarilpirazoles como inibidores da proteína quinase
US8426428B2 (en)	2008-12-05	2013-04-23	Principia Biopharma, Inc.	EGFR kinase knockdown via electrophilically enhanced inhibitors
US7741330B1 (en) *	2009-10-12	2010-06-22	Pharmacyclics, Inc.	Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
MX387728B (es)	2010-06-03	2025-03-18	Pharmacyclics Llc	El uso de inhibidores de la tirosina quinasa de bruton (btk).
CN103313976B (zh)	2010-06-30	2016-11-23	铁木医药有限公司	sGC刺激物
PL2710007T3 (pl)	2011-05-17	2020-06-01	The Regents Of The University Of California	Inhibitory kinazy
EA025496B1 (ru)	2011-05-17	2016-12-30	Принсипиа Биофарма Инк.	Ингибиторы тирозинкиназы
JP2014520863A (ja)	2011-07-13	2014-08-25	ファーマサイクリックス，インク．	Ｂｒｕｔｏｎ型チロシンキナーゼの阻害剤
EP2548877A1 (en)	2011-07-19	2013-01-23	MSD Oss B.V.	4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
US8377946B1 (en)	2011-12-30	2013-02-19	Pharmacyclics, Inc.	Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US20160045503A1 (en)	2012-06-18	2016-02-18	Principia Biopharma Inc.	Formulations containing reversible covalent compounds
WO2014022569A1 (en)	2012-08-03	2014-02-06	Principia Biopharma Inc.	Treatment of dry eye
US20140045813A1 (en) *	2012-08-10	2014-02-13	Boehringer Ingelheim International Gmbh	Heteroaromatic compounds as btk inhibitors
GB201214750D0 (en) *	2012-08-17	2012-10-03	Respivert Ltd	Compounds
HK1211293A1 (en) *	2012-11-02	2016-05-20	辉瑞公司	Bruton's tyrosine kinase inhibitors
CN103848810A (zh) *	2012-11-30	2014-06-11	北京赛林泰医药技术有限公司	鲁顿酪氨酸激酶抑制剂
US8957080B2 (en)	2013-04-09	2015-02-17	Principia Biopharma Inc.	Tyrosine kinase inhibitors
GB201309085D0 (en)	2013-05-20	2013-07-03	Redx Pharma Ltd	Compounds
MX2016004030A (es) *	2013-09-30	2016-10-26	Beijing Synercare Pharma Tech Co Ltd	Inhibidores sustituidos de nicotinamida de btk y su preparacion y uso en el tratamiento del cancer, inflamacion y enfermedad autoinmune.
WO2015075051A1 (en) *	2013-11-19	2015-05-28	Universitaet Des Saarlandes	Allosteric inhibitors of atypical protein kinases c
WO2015095099A1 (en)	2013-12-20	2015-06-25	Merck Sharp & Dohme Corp.	Btk inhibitors
CN112353806A (zh)	2014-02-21	2021-02-12	普林斯匹亚生物制药公司	Btk抑制剂的盐和固体形式
GB201404987D0 (en) *	2014-03-20	2014-05-07	Redx Pharma Ltd	Compounds
CN105085474B (zh) *	2014-05-07	2018-05-18	北京赛林泰医药技术有限公司	鲁顿酪氨酸激酶抑制剂
GB201410430D0 (en)	2014-06-11	2014-07-23	Redx Pharma Ltd	Compounds
TN2017000329A1 (en)	2015-01-28	2019-01-16	Bayer Pharma AG	4h-pyrrolo[3,2-c]pyridin-4-one derivatives
GB2548542A (en) *	2015-06-16	2017-09-27	Redx Pharma Plc	Compounds
JOP20160198B1 (ar)	2015-09-16	2022-03-14	Janssen Pharmaceuticals Inc	مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar)	2015-09-16	2020-08-27	Katholieke Univ Leuven Ku Leuven Research & Development	مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
HK1258779A1 (zh)	2015-09-16	2019-11-22	Loxo Oncology Inc.	用於治療癌症的作為btk抑制劑的吡唑並嘧啶衍生物
CA3005268C (en)	2015-12-16	2024-04-30	Boehringer Ingelheim International Gmbh	Heteroaromatic compounds as btk inhibitors
BR112018012112A2 (pt)	2015-12-16	2018-12-04	Bristol-Myers Squibb Company	heteroaril-hidroxipirimidinonas como agonistas do receptor apj
EP3390348B1 (en)	2015-12-16	2024-04-17	Loveland Products, Inc.	Dendrimer and formulations thereof
SI3390395T1 (sl)	2015-12-16	2020-11-30	Loxo Oncology, Inc.	Spojine uporabne kot inhibitorji kinaz
BR112018010691B1 (pt)	2015-12-16	2023-03-14	Ecolab Usa Inc	Métodos para remover micro-organismos e depósitos minerais e crescimento microbiano

2016
- 2016-12-16 SI SI201630920T patent/SI3390395T1/sl unknown
- 2016-12-16 CN CN202210312064.XA patent/CN114605327B/zh active Active
- 2016-12-16 CN CN202111022488.4A patent/CN113603645B/zh active Active
- 2016-12-16 EP EP20194724.9A patent/EP3782994B1/en active Active
- 2016-12-16 MY MYPI2022003990A patent/MY200590A/en unknown
- 2016-12-16 ES ES16816363T patent/ES2828431T3/es active Active
- 2016-12-16 AU AU2016373530A patent/AU2016373530B2/en active Active
- 2016-12-16 CN CN201680073031.7A patent/CN108473481B/zh active Active
- 2016-12-16 LT LTEP16816363.2T patent/LT3390395T/lt unknown
- 2016-12-16 RS RS20201291A patent/RS60982B9/sr unknown
- 2016-12-16 HR HRP20201835TT patent/HRP20201835T1/hr unknown
- 2016-12-16 MA MA055064A patent/MA55064A/fr unknown
- 2016-12-16 IL IL285976A patent/IL285976B2/en unknown
- 2016-12-16 SG SG10202012498TA patent/SG10202012498TA/en unknown
- 2016-12-16 PE PE2021001592A patent/PE20220502A1/es unknown
- 2016-12-16 CN CN202111022492.0A patent/CN113636978B/zh active Active
- 2016-12-16 PE PE2021001581A patent/PE20220507A1/es unknown
- 2016-12-16 PT PT168163632T patent/PT3390395T/pt unknown
- 2016-12-16 MA MA49809A patent/MA49809A1/fr unknown
- 2016-12-16 MD MDE20181001T patent/MD3390395T2/ro unknown
- 2016-12-16 CN CN202210312076.2A patent/CN114621146A/zh active Pending
- 2016-12-16 CN CN202210311995.8A patent/CN114634447B/zh active Active
- 2016-12-16 PE PE2018001143A patent/PE20181449A1/es unknown
- 2016-12-16 CA CA3008488A patent/CA3008488C/en active Active
- 2016-12-16 ES ES20194724T patent/ES3041897T3/es active Active
- 2016-12-16 KR KR1020187020225A patent/KR102215792B1/ko active Active
- 2016-12-16 NZ NZ743553A patent/NZ743553A/en unknown
- 2016-12-16 HU HUE16816363A patent/HUE051921T2/hu unknown
- 2016-12-16 TN TNP/2018/000213A patent/TN2018000213A1/en unknown
- 2016-12-16 JP JP2018532035A patent/JP6731483B2/ja active Active
- 2016-12-16 EP EP16816363.2A patent/EP3390395B1/en active Active
- 2016-12-16 KR KR1020217003683A patent/KR20210018530A/ko not_active Withdrawn
- 2016-12-16 CO CONC2018/0006164A patent/CO2018006164A2/es unknown
- 2016-12-16 CN CN202210310724.0A patent/CN114716381B/zh active Active
- 2016-12-16 MX MX2018007267A patent/MX380907B/es unknown
- 2016-12-16 EA EA201891268A patent/EA035132B1/ru not_active IP Right Cessation
- 2016-12-16 SG SG11201805044WA patent/SG11201805044WA/en unknown
- 2016-12-16 CN CN202210312050.8A patent/CN114591242B/zh active Active
- 2016-12-16 UA UAA202003795A patent/UA127863C2/uk unknown
- 2016-12-16 CR CR20180367A patent/CR20180367A/es unknown
- 2016-12-16 DK DK16816363.2T patent/DK3390395T3/da active
- 2016-12-16 UA UAA201807294A patent/UA122258C2/uk unknown
- 2016-12-16 MY MYPI2022003989A patent/MY202026A/en unknown
- 2016-12-16 CN CN202210311970.8A patent/CN114573510B/zh active Active
- 2016-12-16 WO PCT/GB2016/053968 patent/WO2017103611A1/en not_active Ceased
- 2016-12-16 MX MX2021003478A patent/MX394193B/es unknown
- 2016-12-16 US US16/063,542 patent/US10695323B2/en active Active
2018
- 2018-06-10 IL IL259923A patent/IL259923B/en active IP Right Grant
- 2018-06-13 PH PH12018501268A patent/PH12018501268A1/en unknown
- 2018-06-14 CL CL2018001591A patent/CL2018001591A1/es unknown
- 2018-06-20 ZA ZA2018/04137A patent/ZA201804137B/en unknown
- 2018-08-22 US US16/109,162 patent/US10342780B2/en active Active
- 2018-08-27 US US16/113,661 patent/US10464905B2/en active Active
2020
- 2020-05-13 US US15/930,657 patent/US10918622B2/en active Active
- 2020-07-06 JP JP2020116636A patent/JP7086140B2/ja active Active
- 2020-07-26 IL IL276283A patent/IL276283B/en active IP Right Grant
- 2020-11-16 CY CY20201101090T patent/CY1123561T1/el unknown
- 2020-12-15 US US17/122,103 patent/US11471441B2/en active Active
2021
- 2021-01-26 ZA ZA2021/00544A patent/ZA202100544B/en unknown
- 2021-02-24 IL IL281067A patent/IL281067B/en unknown
- 2021-03-23 AU AU2021201811A patent/AU2021201811B2/en active Active
- 2021-08-31 AU AU2021225162A patent/AU2021225162B2/en active Active
- 2021-08-31 AU AU2021225161A patent/AU2021225161B2/en active Active
- 2021-10-05 ZA ZA2021/07472A patent/ZA202107472B/en unknown
- 2021-10-05 ZA ZA2021/07471A patent/ZA202107471B/en unknown
- 2021-11-12 US US17/525,350 patent/US11826351B2/en active Active
2022
- 2022-06-07 JP JP2022092275A patent/JP7419437B2/ja active Active
2023
- 2023-07-31 US US18/362,249 patent/US12220401B2/en active Active
2024
- 2024-02-27 HU HUS2400003C patent/HUS2400003I1/hu unknown
- 2024-02-29 NO NO2024008C patent/NO2024008I1/no unknown
- 2024-03-01 FI FIC20240004C patent/FIC20240004I1/fi unknown
- 2024-03-04 FR FR24C1009C patent/FR24C1009I2/fr active Active
- 2024-03-04 CY CY2024003C patent/CY2024003I1/el unknown
- 2024-03-06 LT LTPA2024506C patent/LTPA2024506I1/lt unknown
- 2024-03-06 NL NL301262C patent/NL301262I2/nl unknown
- 2024-11-21 US US18/955,844 patent/US20250090500A1/en active Pending

Also Published As

Publication number	Publication date
KR102215792B1 (ko)	2021-02-16
MX2021003478A (es)	2022-07-25
CY2024003I2 (el)	2024-09-20
MX380907B (es)	2025-03-12
AU2021225161B2 (en)	2023-08-03
FR24C1009I1 (fr)	2024-05-24
UA127863C2 (uk)	2024-01-31
ZA202107471B (en)	2023-03-29
HK1263254A1 (en)	2020-02-21
CN114573510B (zh)	2025-02-25
IL281067A (en)	2021-04-29
US20190000806A1 (en)	2019-01-03
MY200590A (en)	2024-01-04
WO2017103611A1 (en)	2017-06-22
CL2018001591A1 (es)	2018-09-28
ES2828431T3 (es)	2021-05-26
ES3041897T3 (en)	2025-11-17
CN114605327B (zh)	2025-03-11
ZA201804137B (en)	2022-08-31
IL285976B1 (en)	2023-06-01
RS60982B9 (sr)	2025-07-31
NL301262I2 (nl)	2024-04-24
MX2018007267A (es)	2018-11-09
CN114634447A (zh)	2022-06-17
TN2018000213A1 (en)	2019-10-04
EP3390395B1 (en)	2020-09-09
IL281067B (en)	2022-04-01
SG11201805044WA (en)	2018-07-30
EP3782994B1 (en)	2025-07-16
CN113636978A (zh)	2021-11-12
US11471441B2 (en)	2022-10-18
US20190135762A1 (en)	2019-05-09
HUE051921T2 (hu)	2021-03-29
CY1123561T1 (el)	2022-03-24
LTPA2024506I1 (da)	2024-03-25
EP3390395A1 (en)	2018-10-24
US20220062239A1 (en)	2022-03-03
UA122258C2 (uk)	2020-10-12
PE20181449A1 (es)	2018-09-12
JP2020172535A (ja)	2020-10-22
FR24C1009I2 (fr)	2025-02-07
AU2021201811B2 (en)	2022-01-27
CA3008488A1 (en)	2017-06-22
CN114716381A (zh)	2022-07-08
KR20210018530A (ko)	2021-02-17
HUS2400003I1 (hu)	2024-03-28
IL285976A (en)	2021-10-31
FIC20240004I1 (fi)	2024-03-01
HRP20201835T1 (hr)	2021-01-08
MD3390395T2 (ro)	2021-02-28
RS60982B1 (sr)	2020-11-30
AU2021225162A1 (en)	2021-09-30
CN114634447B (zh)	2024-11-15
US10464905B2 (en)	2019-11-05
US10918622B2 (en)	2021-02-16
US20200276162A1 (en)	2020-09-03
CN113636978B (zh)	2024-10-29
EA035132B1 (ru)	2020-04-30
MX394193B (es)	2025-03-21
CY2024003I1 (el)	2024-09-20
AU2021201811A1 (en)	2021-04-22
JP2022120013A (ja)	2022-08-17
PT3390395T (pt)	2020-11-03
US10695323B2 (en)	2020-06-30
NZ743553A (en)	2022-08-26
JP7086140B2 (ja)	2022-06-17
CO2018006164A2 (es)	2018-09-20
CN108473481B (zh)	2022-04-19
MA49809A1 (fr)	2021-08-31
MA55064A (fr)	2021-09-29
US20210093611A1 (en)	2021-04-01
IL285976B2 (en)	2023-10-01
US20180362512A1 (en)	2018-12-20
EP3782994A1 (en)	2021-02-24
MY202026A (en)	2024-03-29
EA201891268A1 (ru)	2018-11-30
BR112018012341A2 (pt)	2018-12-04
CN114573510A (zh)	2022-06-03
SI3390395T1 (sl)	2020-11-30
JP7419437B2 (ja)	2024-01-22
SG10202012498TA (en)	2021-01-28
JP6731483B2 (ja)	2020-07-29
PH12018501268A1 (en)	2019-02-18
CN108473481A (zh)	2018-08-31
JP2018538307A (ja)	2018-12-27
IL276283A (en)	2020-09-30
ZA202100544B (en)	2023-06-28
US10342780B2 (en)	2019-07-09
CN114716381B (zh)	2025-03-11
AU2016373530A1 (en)	2018-07-05
AU2021225161A1 (en)	2021-09-30
CN114591242A (zh)	2022-06-07
US20230372298A1 (en)	2023-11-23
PE20220507A1 (es)	2022-04-07
US20250090500A1 (en)	2025-03-20
CN114621146A (zh)	2022-06-14
KR20180115261A (ko)	2018-10-22
AU2021225162B2 (en)	2023-08-03
CR20180367A (es)	2018-11-12
US11826351B2 (en)	2023-11-28
CN114591242B (zh)	2025-01-07
LT3390395T (lt)	2020-11-25
IL259923A (en)	2018-07-31
US12220401B2 (en)	2025-02-11
IL276283B (en)	2021-03-25
CN113603645B (zh)	2024-10-29
NO2024008I1 (no)	2024-02-29
IL259923B (en)	2020-08-31
ZA202107472B (en)	2023-03-29
PE20220502A1 (es)	2022-04-07
AU2016373530B2 (en)	2021-01-21
CN114605327A (zh)	2022-06-10
CA3008488C (en)	2023-10-10
CN113603645A (zh)	2021-11-05

Publication	Publication Date	Title
CY2024003I1 (el)	2024-09-20	Ενωσεις χρησιμες ως αναστολεις κινασης
DK3710446T3 (da)	2022-08-01	Forbindelser, der kan anvendes til at hæmme CDK7
LT3580220T (lt)	2021-12-27	Aminotriazolopiridinai, kaip kinazės inhibitoriai
DK3303348T3 (da)	2019-11-11	Naphthyridinforbindelser som JAK-kinaseinhibitorer
DK3371190T3 (da)	2022-05-23	Heterocykliske forbindelser som pi3k-gamma-inhibitorer
DK3442980T3 (da)	2021-08-30	Heterocykliske forbindelser som ret-kinase-hæmmere
DK3303334T3 (da)	2021-06-28	Tyrosinkinasehæmmere
DK3298002T3 (da)	2021-02-15	Heterocykliske amider som kinasehæmmere
DK3277677T3 (da)	2021-05-25	1-cyano-pyrrolidinforbindelser som usp30-hæmmere
PL3209656T3 (pl)	2020-12-14	Związki indolo-karboksyamidu użyteczne jako inhibitory kinazy
LT3105226T (lt)	2019-11-11	Ciklopropilaminai, kaip lsd1 inhibitoriai
CL2016002502A1 (es)	2017-06-23	Inhibidores de biaril cinasa
HUE050842T2 (hu)	2021-01-28	Janus-kináz inhibitor
DK3105218T3 (da)	2019-11-04	Cyclopropylaminer som lsd1-inhibitorer
DK3313832T3 (da)	2021-04-19	3-tetrazolyl-benzen-1,2-disulfonamidderivater som metallo-beta- lactamase-hæmmere
DK3235819T3 (da)	2020-12-07	Pyrrolopyrimidinforbindelser, der er anvendelige som JAK-inhibitorer
LT3704118T (lt)	2022-02-25	Aminoimidazopiridazinai, kaip kinazės inhibitoriai
DK3341379T3 (da)	2019-12-02	EZH2-hæmmere
LT3386991T (lt)	2020-08-25	Policikliniai junginiai, kaip brutono tirozinkinazės inhibitoriai
DK3288944T3 (da)	2019-07-22	Imidazopyrazinoner som pde1-inhibitorer
DK3544981T3 (da)	2021-09-20	Benzodiazoliumforbindelser som enac-inhibitorer
DK3458460T3 (da)	2021-03-01	Imidazoler som histondemethylase-inhibitorer
DK3497091T3 (da)	2020-10-19	Kondenserede thiophen-derivater, der kan anvendes som NAPI-IIB-hæmmere
LT3347360T (lt)	2020-01-27	Junginiai, naudingi ror-gama-t slopinimui
DK3237407T3 (da)	2020-07-20	3,5-diaminopyrazolkinasehæmmere